Immucell (ICCC) Enterprise Value (2010 - 2026)

Immucell (ICCC) has reported Enterprise Value for 17 consecutive years, with $82.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 44.69% year-over-year to $82.4 million; the trailing twelve-month figure through Jun 2026 stood at $82.4 million (up 44.69% YoY), and the FY2025 full-year result was $51.8 million, up 21.99% from the prior year.
• Enterprise Value rose to $82.4 million in Q2 2026 per ICCC's latest filing, from $51.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at $82.4 million in Q2 2026 and bottomed at $28.3 million in Q3 2024.
• Historically, Enterprise Value has averaged $46.6 million across 5 years, with a median of $41.5 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value slumped 41.37% in 2023, then soared 86.34% in 2025.
• Over 5 years, Enterprise Value stood at $41.5 million in 2022, then dropped by 7.21% to $38.5 million in 2023, then climbed by 10.43% to $42.5 million in 2024, then climbed by 21.99% to $51.8 million in 2025, then surged by 59.03% to $82.4 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $82.4 million, $51.8 million, and $52.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.